1-4 of 4
Yu-Jun Dai
Close
Sort by
Journal Articles

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation

Qian Jiang, Zongru Li, Yue Hou, Yu Hu, Weiming Li, Xiaoli Liu, Na Xu, Yanli Zhang, Yongping Song, Li Meng, Zhenya Hong, Bingcheng Liu, Yan Li, Suning Chen, Mengxing Xue, Huanling Zhu, He Li, Xin Du, Jin Lou, Xiaohan Zhang, Yang Liang, Yu-Jun Dai, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiao-Jun Huang
Journal: Blood
Blood (2022) 140 (Supplement 1): 203–204.
https://doi.org/10.1182/blood-2022-170698
Published: 2022
Journal Articles

An Immune Risk Score Predicts Survival of Patients with Myelodysplastic Syndrome

Yang Liang, MD, Fang Hu, Yu-Jun Dai, PhD, Yun Wang, MD PhD, Huan Li
Journal: Blood
Blood (2020) 136 (Supplement 1): 33–34.
https://doi.org/10.1182/blood-2020-137349
Published: 2020
Journal Articles

Identification of an Immune Risk Score to Predict the Prognosis of Acute Myeloid Leukemia

Yang Liang, PhD, Yun Wang, Yan-Yu Cai, Siliang Chen, Run-Cong Nie, Zhe-Yuan Qin, PhD, Fang Hu, Weida Wang, MD, Yu-Jun Dai, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 708.
https://doi.org/10.1182/blood-2019-126733
Published: 2019
Journal Articles

A Distinct Metabolic Signature in DNMT3A-Mutated Leukemia

Yu-Jun Dai, PhD, Fang Hu, Si-Yuan He, Xiao-Peng Tian, Hong-Hong Li, Ze-Yuan Qin, Siliang Chen, Yang Liang, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1426.
https://doi.org/10.1182/blood-2019-121657
Published: 2019